AVB-002 / Avenge Bio - LARVOL DELTA

Avenge Bio to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting (PRNewswire) - "Avenge Bio, Inc...announced their poster presentation at the Society of Immunotherapy of Cancer 38th Annual Meeting (SITC 2023) on November 1-5, 2023, in San Diego, California....Avenge is currently enrolling patients in a First-in-Human, Phase 1/2, multicenter clinical trial (NCT05538624) designed to evaluate the safety and efficacy of AVB-001. The Company has advanced through multiple dose levels in a dose escalation cohort and expects to initiate a Phase 2 dose expansion trial in 1H 2024....The poster will present how a single administration of either AVB-001 or AVB-002, engineered to produce native human IL-2 or native human IL-12 respectively, demonstrated complete responses as monotherapy and provided sustained eradication in various mouse tumor models. In addition, the poster will also present the commonalities and differences between AVB-001 and AVB-002 in modulating the innate and adaptive anti-tumor immune response."

Preclinical • Trial status • Oncology